Though polio has been nearly eradicated from the globe, researchers have made a troubling discovery that underscores the need to boost vaccination rates in countries that have seen recent outbreaks as well as develop new, more potent vaccines.
As the Ebola outbreak continues to claim victims in West Africa, governments and industry alike are racing toward a therapeutic or preventive drug that could help halt its deadly spread and avert future human crises involving the virus.
As the U.S. continues to experience the highest number of measles cases this year since the highly contagious viral illness was eliminated nationwide in 2000, health officials and researchers are looking for ways to keep vaccination rates in check.
With recent outbreaks in the Caribbean and the Pacific, the U.S. Centers for Disease Control and Prevention is concerned that the number of chikungunya cases among travelers will continue to rise. But results from an early-stage clinical trial point to a promising vaccine that may be able to prevent transmission of the disease.
As Africa continues to experience the most severe Ebola outbreak in the disease's short history, the World Health Organization has deemed it ethical to offer unregistered interventions as potential treatments or preventive therapies, including investigational vaccines.
The U.S. National Institutes of Health is set to begin an early-stage clinical trial for an Ebola vaccine in September, according to reports.
Although GlaxoSmithKline has submitted its malaria vaccine to the European Medicines Agency for approval, the jab hasn't shown as much promise as hoped, underscoring the need for a better understanding of the malaria parasite and how it affects the human immune system.
It's taken 30 years, but GlaxoSmithKline's experimental malaria vaccine is finally ready for regulatory review. Looking to bring the world's first shot for the mosquito-borne disease to market, the pharma giant said Thursday that it has submitted its candidate for approval.
The discovery of vials of "variola," commonly known as smallpox, in a storage room at the National Institutes of Health in Bethesda, MD, has raised new concerns that the virus could be used in a bioterrorism attack.
International debate is brewing over whether to give experimental vaccines to people in regions of the current Ebola outbreak in West Africa in an effort to thwart the spread of the deadly virus.